TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors and new institutional investors, foundations, pensions, and endowments. With the close of Fund III, TCGX has now raised more than $3.1 billion in total capital since its founding in 2021.

TCGX Fund III exceeded its initial target, underscoring strong global investor demand. The fundraise marks a significant milestone and is an endorsement of the differentiated strategy and TCGX’s fully flexible mandate to invest across both private and public markets.

“Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.”

“We are grateful to our investors for their support and appreciate the hard work from our portfolio company operators to enable this accomplishment. With Fund III, we look forward to investing in the next generation of biotechs developing transformative therapies for patients,” said Cariad Chester, Managing Partner at TCGX.

As part of this milestone, TCGX is proud to announce the promotion of Giuliano Marostica to Managing Partner. “Giuliano was the first team member to join me at TCGX, and he has played an integral role in building the firm and bringing tremendous value to our portfolio companies,” said Dr. Yu.

CFO/COO Craig Skaling added, “We are fortunate to have built a world-class team at TCGX. Their commitment and talent drive our ability to scale effectively and partner with companies advancing innovative science.”

About TCGX

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. The firm has offices in Palo Alto, San Francisco, and New York City. For more information, please visit www.tcgcrossover.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006796721/en/

Media Contact:
Edward Amorosi, Head of Capital Formation & Investor Relations at TCG Crossover (“TCGX”)
eamorosi@tcgcrossover.com

Logo

Tags

More Like This

Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia

PX3 Partners reaches €1.1 billion of assets under management with its inaugural fundraise

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

InTandem Capital Partners Closes Fund III at $715 Million

Cocoon Capital Raises Over Half of Its USD 50M Fund III Backing High-Performing Enterprise and Deep Tech Startups

G Squared Closes $1.1B Sixth Flagship Fund to Capitalize on Opportunity in Venture Capital Secondaries

Hadean Ventures announces oversubscribed final close of Hadean Capital II - a fund dedicated to investments in life science start-ups across Europe

Appian raises US$2.06 billion for Fund III, more than doubling AUM